Bonnie Anderson, Chairman of the Board and Chief Executive Officer, Veracyte

Bonnie Anderson Headshot and Veracyte LogoBonnie H. Anderson is Chairman and Chief Executive Officer of Veracyte, a leading genomic diagnostics company that improves the lives of patients by providing answers to challenging clinical questions. The company’s first-to-market tests are developed using RNA whole-transcriptome sequencing and machine learning and are transforming care in thyroid cancer, lung cancer and idiopathic pulmonary fibrosis where they improve diagnosis and inform treatment decisions. Ms. Anderson’s career spans over 30 years in regulated diagnostics and life science markets. She cofounded Veracyte in 2008 and served as the company’s President and Chief Executive Officer until 2016, when she was also appointed Chairman of the Board. She led Veracyte’s initial public offering in 2013 and has spearheaded commercialization of Veracyte’s market-leading products.

Prior to Veracyte, Ms. Anderson provided strategic consulting services to venture capital firms and early-stage businesses following 18 years in leadership positions at Beckman Coulter. She serves on the boards of the Biotechnology Innovation Organization (BIO) and Castle Biosciences and is President of the Coalition for 21st Century Medicine. She is a trustee emeritus of the Keck Graduate Institute of Applied Life Sciences. Ms. Anderson graduated from Indiana University of Pennsylvania with a Bachelor of Science degree in Medical Technology and in 2012 was honored with a “Distinguished Alumni” award. She has received numerous awards for her industry leadership, including: the Wallace H. Coulter Award for Healthcare Innovation (2017); “Fiercest Women in Life Sciences” (FiercePharma 2017); “100 Most Creative People in Business” (Fast Company, 2015); “Most Influential Women in Bay Area Business” and “Bay Area’s Most Admired CEOs” (San Francisco Business Times, 2013 and 2014); and “Women of Influence” (Silicon Valley Business Journal, 2013). Under Ms. Anderson’s leadership, Veracyte has been named a “Top Workplace” by the Bay Area News Group, based solely on employee feedback, for six consecutive years (2014-2019).

Kathy Behrens Wilsey, CEO and Founder, KEW Group

c21cm_leadership_behrens-wilsey-kew-group_225x322_01Prior to co-founding KEW Group as CEO, Dr. Behrens Wilsey served as a managing partner of venture funds at Robertson Stephens Investments, the president and chair of the National Venture Capital Association, and a member of the President’s Council of Advisors on Science and Technology.

Brook Byers, Partner, Kleiner Perkins Caufield & Byers

c21cm_leadership_byers-kpcb_225x353_01Brook Byers is a founding member of Kleiner Perkins Caufield & Byers. A venture capital investor since 1972, Brook has been closely involved with more than 60 new technology-based ventures, many of which have become public companies. He formed the first life sciences practice group in the venture capital profession in 1984 and led KPCB to become a premier venture capital firm in the medical, healthcare, and biotechnology sectors. KPCB has invested in and helped build more than 110 life sciences companies that have developed hundreds of products to treat underserved medical needs for many millions of patients. Brook was the founding president and then chairman of four biotechnology companies that were incubated in KPCB’s offices and went on to become public companies with an aggregate market value of more than US$8 billion. He serves on the board of directors of CareDX, Enjoy, Newsela, Oculeve, Pacific Biosciences, Inc., and Zephyr Health.

Formerly, Brook served as a director of Idec Pharmaceuticals (chairman), Athena Neurosciences (chairman), Signal Pharmaceuticals, Onyx Pharmaceuticals, Hybritech (chairman), Genprobe, and others. These companies pioneered the medical use of molecular biology, monoclonal antibodies, personalized medicine, molecular diagnostics, genomics, and sequencing. He also previously served as the president and a director of the Western Association of Venture Capitalists.

Brook is on the Board of Trustees of Stanford University. He also serves on the Board of Overseers of the University of California San Francisco medical campus and hospitals and the Board of Directors of the New Schools Foundation.

In 2007, UCSF awarded Brook the UCSF Medal, its honorary degree equivalent. In 2008, Brook was elected a fellow of the American Academy of Arts and Sciences. In 2009, he received the Lifetime Achievement Award from the National Venture Capital Association. In 2010, he received an honorary Ph.D. from Georgia Institute of Technology.

Brook is a former director of the Entrepreneurs Foundation, the Asian Art Museum in San Francisco, and the Georgia Tech Advisory Board. He was also a founder of TechNet.

Raised in Atlanta, Georgia, Brook graduated with a bachelor’s degree in electrical engineering from Georgia Tech and received an M.B.A. from Stanford University. When not at work, Brook enjoys listening to musicians Eric Clapton, Jack Johnson, B.B. King, Alison Krauss, the Rolling Stones, Yo-Yo Ma, the Grateful Dead, and the Allman Brothers Band. His favorite web sites include www.newschools.org, www.calacademy.org, www.ucsf.edu, www.womenforwomen.org, www.acumenfund.org, www.climateproject.org, and www.edf.org.

Kim Popovits, Former President and CEO, Genomic Health

c21cm_leadership_popovits-genomic_225x338_01Committed to changing the paradigm of cancer care, Kim Popovits has led Genomic Health in revolutionizing the treatment of cancer through genomic-based diagnostic tests for breast, colon, and prostate cancers that address the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today. Kim has served as Genomic Health’s Chairman of the Board since 2012, and Chief Executive Officer and President since 2009. She was President and Chief Operating Officer since joining the company in 2002. Prior to joining Genomic Health, Kim served as Senior Vice President, Marketing and Sales at the biotechnology company, Genentech, Inc. During her 15 years at Genentech, Kim led the successful commercialization of 14 new therapies, including Herceptin┬«, the revolutionary targeted treatment that changed the way doctors treat a particularly aggressive form of breast cancer. Before joining Genentech, Kim served as division manager for American Critical Care, a division of American Hospital Supply Corporation. Kim currently serves on the boards of the California Life Sciences Association (CLSA), the Personalized Medicine Coalition (PMC), the American Clinical Laboratory Association (ACLA), and ZS Pharma. Kim is also the President of The Coalition for 21st Century Medicine, and serves as an Advisor to the Healthcare Businesswomen’s Association (HBA). Kim’s contributions to science and the commercialization of the biotechnology industry have been acknowledged by multiple organizations including being named Most Admired CEO in 2014 as well as one of the Most Influential Women in the Bay Area from 2006-2012 by the San Francisco Business Times. She was also named Woman of the Year in 2008 by the Women Health Care Executives. Kim holds a Bachelor of Arts degree in Business from Michigan State University.

Chad Robins, CEO and Co-Founder, Adaptive Biotechnologies

Chad Robins co-founded Adaptive Biotechnologies in September 2009 and has served as Chief Executive Officer and a member of the board of directors since incorporation. Prior to co-founding Adaptive, Chad held numerous executive-level positions in medical technology, investment, and real estate companies. Chad holds an MBA from The Wharton School at the University of Pennsylvania and a BS in Managerial Economics from Cornell University.

Sharon Terry, President and CEO, Genetic Alliance

c21cm_leadership_terry-genetic-alliance_225x318_01Sharon F. Terry is President and CEO of Genetic Alliance, a network of more than 10,000 organizations, of which 1,200 are disease advocacy organizations. Genetic Alliance engages individuals, families, and communities to transform health.

She is the founding CEO of PXE International, a research advocacy organization for the genetic condition pseudoxanthoma elasticum (PXE). PXE affects Terry’s two adult children. As co-discoverer of the gene associated with PXE, she holds the patent for ABCC6 to act as its steward and has assigned her rights to the foundation. She developed a diagnostic test and conducts clinical trials. She is the author of 140 peer-reviewed papers, of which 30 are PXE clinical studies.

Terry is also a co-founder of the Genetic Alliance Registry and Biobank. In her focus at the forefront of consumer participation in genetics research, services, and policy, she serves in a leadership role on many of the major international and national organizations, including the Accelerating Medicines Partnership, Institute of Medicine (IOM) Science and Policy Board, the IOM Roundtable on Translating Genomic-Based Research for Health, the PubMed Central National Advisory Committee, the PhenX scientific advisory board, the Global Alliance for Genomics and Health, the International Rare Disease Research Consortium Executive Committee, and as Founding President of EspeRare Foundation of Geneva, Switzerland. She is on the editorial boards of several journals and is an editor of Genome. She led the coalition that was instrumental in the passage of the Genetic Information Nondiscrimination Act. She received an honorary doctorate from Iona College for her work in community engagement in 2006; the first Patient Service Award from the UNC Institute for Pharmacogenomics and Individualized Therapy in 2007; the Research!America Distinguished Organization Advocacy Award in 2009; and the Clinical Research Forum and Foundation’s Annual Award for Leadership in Public Advocacy in 2011. In 2012, she became an honorary professor of Hebei United University in Tangshan, China, and also received the Facing Our Risk of Cancer Empowered (FORCE) Spirit of Empowerment Advocacy Award. She was named one of FDA’s “30 Heroes for the Thirtieth Anniversary of the Orphan Drug Act” in 2013. In 2012 and 2013, Terry won $400,000 in first prizes in three large competitions for the Platform for Engaging Everyone Responsibly (PEER). PEER was awarded a $1M contract from PCORI in 2014.

Terry is an Ashoka Fellow. With her husband Patrick, she is an avid paragliding pilot, rock climber, and weekend farmer.